# Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

> **NCT02962661** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 72 (estimated)

## Conditions studied

- Cardiomyopathy
- Heart Failure
- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm

## Interventions

- **OTHER:** Best Practice
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Mesenchymal Stem Cell Transplantation
- **DRUG:** Mesenchymal Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT02962661
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-18
- **Primary completion:** 2026-07-30
- **Final completion:** 2026-07-30
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02962661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02962661, "Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02962661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*